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L. Berardinelli1,2*1Division of Vascular Surgery and Kidney Transplantation, Policlinico University Hospital Foundation,
IRCCS, Via Francesco Sforza 35, 20122 Milan, and 2General Surgery and Organ Transplantation,
University of Milan, Milan, ItalyApart from long-term central venous catheterisation, the insertion of an arteriovenous graft (AVG) remains the only option
to allow continued haemodialysis when the patient’s superficial veins have been exhausted. Although, expanded PTFE has
become the graft of choice for haemodialysis access throughout the world, many other organic or semi-organic materials are
currently available for AVG construction. These are less prone to steal syndrome, easier to handle, more resistant to infection
and may have similar, if not better, long term patencies.Keywords: Vascular access; Haemodialysis; Prosthetic grafts.Introduction
The best prosthetic material for arteriovenous graft
fistula (AVG) construction in patients on chronic
haemodialysis (HD) with unsuitable superficial
vessels remains a matter for debate, as there have
been no large prospective, randomized trials; more-
over, the materials have been used under different
circumstances and the methods for reporting patency
have not been uniform. This review covers currently
available autogenous, allogenic, xenogenic or syn-
thetic grafts for AVG construction, including some that
have been abandoned in favour of new materials with
better compliance and fewer complications.1Graft Materials
The ideal vascular graft for patients on HD should be
easy to handle, closely mimicking the native vessels,
nonthrombogenic, immunologically inert, resistant toenal Access and Transplantation—one of a series of
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strength, and manufactured at a reasonable cost.Biological grafts
Autogenous greater saphenous vein would appear to
be the obvious conduit for AV bridge graft construc-
tion but has generally given disappointing results
with patency rates of 20% at 2 years,2 although
cumulative patencies of 89, 89 and 72% have been
reported at 1–3 years, respectively, in a recent small
retrospective review of forearm AVGs.3 Saphenous
vein can also been used to construct a spiral vein
graft in the lower limb, which gives encouraging
patency at 5 years.4 However, the increased operat-
ing time for saphenous vein harvesting, delayed
healing of the thigh wound, and the need to preserve
it for peripheral vascular or coronary arterial
revascularization have turned attention to other
vascular substitutes.
Homologous saphenous veins, obtained by strip-
ping varicose veins, has been used with excellent
results, whether prepared ‘in house’5–7 or commer-
cially (Vascogref, Bioprotec, Varivas). We have found
that them easy to handle and it is not rejected
immunologically, although other investigators have
found them to cause allosensitization.8Eur J Vasc Endovasc Surg 32, 203–211 (2006)
doi:10.1016/j.ejvs.2006.01.001, available online at http://www.sciencedirect.com onved.
Fig. 1. An organic prosthesis of 6 mm in diameter is
anastomosed to the left brachial artery of 2.9 mm. The
arteriotomy should not be over 2.3 mm, to reduce the risk of
steal syndrome.
L. Berardinelli204Denatured homologous vein grafts have given
variable results with one-year primary patencies of
30–57%.9,10
Initial enthusiasm for cryopreserved venous homo-
grafts (saphenous or femoral vein), with reports of
a two-year cumulative patency of 100% without
allograft rejection10,11 has been tempered by subsequent
reports of graft infections and allograft rupture.12
Denatured arterial homografts have also been given
poor results due to an inflammatory response and
interactions between host and graft cells, and graft
degeneration.13
Human umbilical vein, first used by Dardik,14
showed poor overall patency rates in two early
studies, with frequent thrombosis and infection rates
of over 20% in a mean 8.5 month follow-up.15,16
Moreover, it is expensive and difficult to handle
because of the disparity in thickness between the
umbilical vein and the host vessels.
Bovine Carotid Artery, a pre-treated heterograft,
was first described for AVG construction in 1972. The
long term patency rates were inferior to other graft
materials and it suffered graft disintegration,17
although overall patencies of 79, 69, 63 and 51% at
1–4 years, respectively, were observed by some
investigators.18 On the other hand, Metha reported a
primary patency for bovine carotid grafts of 16% and
the secondary patency of 39%, at 3 years in a large
retrospective study in 1991,19 which is significantly
inferior to those reported for PTFE (22 and 54%). Other
prospective studies have shown these two graft
materials to give similar results20 but bovine carotid
artery is now rarely used,21 due to the high incidence
of aneurysms22 and infections in up to 25%.23
Biohybrid and bioresorbable prostheses, graft
pretreatment with endothelial cell culture, methods
of affixing antibiotics, anticoagulants and growth
factor to graft surfaces are under investigation to
enhance the results of prosthetic vascular materials, as
biologic materials facilitate cell repopulation and
tissue remodeling.
The Omniflow prosthesis is formed from gluter-
aldehyde-tanned ovine collagen, which is grown
around a polyester mesh. This biosynthetic device
obtained by inserting polyester mesh-covered man-
drils beneath the cutaneous truncimuscle ofAustralian
adult sheep for a period of 12–14 weeks, is stabilized
using gluteraldehyde and may be prepared in straight
or J- or U- curved configurations; this collagen-
encapsulated graft is easy to handle, with reduced
thrombogenicity, low rates of infection, a low incidence
of aneurysm formation and satisfactory long-term
results with overall patencies of 77–71% and 48–45%
at one and 4 years.24 The current Omniflow II vascularEur J Vasc Endovasc Surg Vol 32, August 2006graft has a more resistant mesh but requires delicate
manipulation, avoiding cross clamping the graft with
metal instruments and traction during the passage
through the tunnel.
Another modern bioprosthesis, bovine mesenteric
vein, obtained by a patented process of gluteraldehyde
cross linking and gamma radiation has physiological
properties similar to those of the human saphenous
vein, due to its high elastin to collagen ratio. In a recent
multicenter study comparing it with synthetic grafts,
bovine mesenteric vein had lower rates of re-operation
per year (0.97 with bovine mesenteric vein vs 1.37 for
synthetic), a lower incidence of thrombosis (0.78 vs
1.36), a 3.7 fold less frequent infection (0.05 vs 0.2) and
higher patencies, both primary (36 vs 28% at 12
months) and secondary (66 and 60% vs 56 and 43%
at 12 and 24 months, respectively).25
The original bovine ureteric graft, prepared by
gluteraldehyde fixation and detergent processing was
prone to aneurysmal changes.26 A modified prep-
aration procedure to chemically-fix and decellularize
the graft (synergraft),27 eliminates this problem and
has been recently adopted, because of optimal
handling characteristics, the uniform diameter, the
correct thickness of the graft wall to withstand even
high arterial pressures and the absence of valves or
tributaries. In the early preparation, this modified
xenograft, showed reversible edema of the limb and a
redness of the overlying skin in about 40% of limbs in
which the graft had been implanted but this problem
seems to have been overcome by further modifi-
cations. Additional advantages of this graft are the
virtually unlimited supply, the simple storage, no need
of time-consuming preparation or rinsing procedures
and high resistance to infection.
Fig. 3. A forearm PTFE loop graft: (A) the arterial
anastomosis (a) between a tapered e-PTFE and the right
brachial artery has been completed. Some oozing of blood
Fig. 2. A straight AVG in the upper arm in a child, showing
the ‘pleating’ of the organic prosthesis during the arterial
anastomosis to taper the graft and match it to the
arteriotomy.
AV Grafts for Dialysis 205Modern biological materials, such as bovine ureter,
cryopreserved vein12 and bovine mesenteric vein28
show less anastomotic site compliance mismatch, a
reduced tendency to thrombose, reduced intimal
hyperplasia at the venous end of the AVG,29 a reduced
risk of steal syndrome due to the ability to ‘pleat’
the graft (Figs. 1 and 2) thereby reducing its diameter
to match a smaller arteriotomy,30–32 a reduced risk of
infection, a considerable reduction in re-operations to
maintain the patency and better results than PTFE.25,33through the PTFE can be seen. The venous anasomosis (b) is
to a vena comitans of the brachial artery (rather than the
cephalic or basilic veins since if these were present an
autologous brachial fistula would have been constructed).
(B) The completed PTFE loop after skin closure showing the
graft in a subcutaneous tunnel in the forearm, with a distal
counter-incision. The scars of previous failed access sites are
also seen.Synthetic grafts
The modern era of synthetic vascular grafts began
with the search for an inert graft material, but it was
soon realized that healing of vascular prostheses
occurs by interaction with the blood elements and
the surrounding tissue,34 leading to incorporation and
endothelialization of the graft.
Polytetrafluoroethylene (PTFE) (Fig. 3) gained
popularity as graft material in the expanded form
(ePTFE), due to increased porosity, better tissue
adhesion, the lack of requirement to preclot prior to
implantation and improved pliability, in comparison
with polyethylene terephthalate (Dacron).
Expanded PTFE was first used as a conduit for
vascular access in the late 1970’s33 and has since
become the most popular graft material, despite its
high incidence of occlusion, (usually due to myointi-
mal hyperplasia at the venous end), seroma formation,
high infection rates and suboptimal patency rates.
Primary patency rates of 28% at 12 months have been
reported for ePTFE AVGs25 with secondary patency
rates of 76% at 6 months,35 55–59% at 12 months25,36,37
and 43% at 24 months,25, respectively.Further modifications of standard PTFE have been
introduced (impra or goretex, thin walled, tapered,
stretch, higher porosity PTFE, carbon-coated, heparin-
bounded, fibroblast growth factors impregnation, the
addition of external rings to enhance kinking and crush
resistance) but have failed to improve patency.38,39
Similarly, other PTFEmodifications, such as the diastat
graft, which is a self-sealing PTFE-silicone graft, and
plasma-TFE, developed to allow an early cannulation
and avoid the need for temporary dialysis catheter, had
patency rates similar to standard PTFE. The addition of
an expanded cuff to a PTFE graft (Venaflow) to obviate
the problem of outflow venous stenosis has been found
to improve patency.40
The Hemasitew, a transcutaneous button, as
external part of a titanium nonthrombogenic tube,
connected to the side of a PTFE internal arteriovenous
bypass graft with the advantage of avoiding the need
for skin puncture41 is no longer available.Eur J Vasc Endovasc Surg Vol 32, August 2006
Fig. 4. The ‘O’ shaped AVG in the distal third of the upper
arm preserves more proximal sites for potential future
straight AVGs. The compliance of the biological graft is
crucial for this technique, as the prosthesis is placed between
the brachial artery and its vena comitans in a very narrow
loop. This AVG is functioning well at 9 years.
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vascular grafts (vascugraft) was hydrolytically
unstable. A polyether-based polyurethane (Pulse-
Tec), relatively insensitive to hydrolysis, used for
AVGs, underwent biodegradation in vivo due to an
oxidative process.42 One of the latest attempts to create
a self-sealing vascular access for immediate use is a
three-layered polyetherurethaneurea with non-porous
layer under the luminal surface (Vectraw, made by
Thoralonw) gave similar patency rates compared to
PTFE grafts.43 Such polyurethane grafts elongate with
time and the incidence of pseudointima formation near
the venous anastomosis is higher than for ePTFE grafts.
Moreover, early cannulation seems to damage the graft
material as shown by color Doppler ultrasound.44
A more porous polyurethane vascular graft coated
with a gelatin-heparin matrix and reinforced on the
outside with knitted dacron fibers to prevent aneur-
ysm formation (corvita), seems to have no clinical
advantage over PTFE, with a reported cumulative
patency of 53% at 1 year45 and a similar long term
patency.46 Another major concern about polyurethane
grafts is the potential carcinogenic effect of 2,4-toluene
diamine, one of its degradation products.47
Despite major advances in vascular grafting, the
search of small diameter vascular substitutes is far
from complete.Graft Configurations
The forearm loop between the brachial artery and one
of the available veins in the antecubital fossa (Fig. 3 (A)
and (B)) and the straight AVG in the upper arm
between the brachial artery and the axillary vein
(Fig. 2) (or the proximal brachial or basilic vein) are the
most popular graft configurations, but a number of
anatomical variations may be used, depending on the
patient’s remaining vessels. Greater secondary paten-
cies have been reported with the looped forearm AVG
by most48–50 but not all observers.51 However, every
effort should be made to preserve the available vessels
of uremic patients by creating the most distal AV graft
or fistula possible, and adopting a strategy for a
sequential graft placement.52
The straight forearm configuration between the
radial artery at the wrist and an antecubital vein53
should be avoided, because of an increased risk of
early thrombosis. Ischaemia due to steal syndrome is
also a problem because of the relatively poor inflow
through the radial artery. Ideally, one of the venae
comitantes of the brachial artery should be used rather
than the superficial veins as outflow for a straight or
looped forearm AVG graft, because if the basilic orEur J Vasc Endovasc Surg Vol 32, August 2006cephalic veins are still available they should be used
instead to construct an autogenous AVF with the
brachial artery.
The elasticity and compliance of the graft are crucial
for some techniques, such as the ‘O’ shapedAVGwith a
narrow loop in the distal third of the upper arm (Fig. 4)
between the brachial artery and its vena comitans or the
basilic vein,52 in order to preserve more proximal
locations for potential future straight AVGs. Modern
biological grafts are more suited to this configuration.
AVGs in the lower limb have generally given less
encouraging results than for the upper limb, because
of increased rates of infection (41%), ischaemia (11%),
and 2-year primary and secondary patency rates of
only 19 and 54%, respectively.54 However, groin access
is a useful option when upper extremities are
unavailable and peritoneal dialysis has failed.
The lower extremity may be also used for a
saphenous vein loop fistula between great saphenous
vein anastomosed in an end-to-side fashion to
superficial femoral artery55,56 or to the popliteal
artery.57 However, prosthetic grafts shorten the
operation time, reduce wound-healing problems and
preserve the saphenous vein for future myocardial or
peripheral revascularization.
A careful policy of native vessel preservation
should also be adopted in the lower limb to maximize
the use of potential access sites in each extremity: the
distal superficial femoral artery and saphenous vein
should be used first for positioning an AVG in a
straight configuration, as his subsequently converted
to a loop configuration after failure, leaving a segment
of the old AVG temporary to allow early needling and
minimize the use of a central venous catheter.52 The
AV Grafts for Dialysis 207common femoral artery and superficial femoral vein
may be also employed, if necessary, for a looped AVG.
The axillary (or subclavian) artery can be used for a
loop AVG, with the ipsilateral axillary or jugular vein
as outflow, as well as for placing a straight AVG
anastomosed to the contralateral axillary or jugular
veins.58,59
Long axillo-femoral grafts60 are prone to repeated
thromboses, especially in hypotensive patients. More-
over, when large vessels, such as the axillary artery
and femoral veins, are employed severe venous or
arterial problems may follow AVG thrombosis.61
Central vein occlusion, ischaemic steal syndrome
and cardiac failure may be indications for creating
arterio-arterial vascular access grafts run superficially
in the lower limb,62 or on the chest wall.63
More heroic access configurations, such as anasto-
mosis to the right atrial appendage through a median
sternotomy64 and to the renal vein65 to bypass central
venous obstruction should be avoided if possible in
favour of a permanent central venous catheter.Graft complications
There are differences between graft materials with
regard to the type and the incidence of complications.
The high surface thrombogenicity of the AVG may be
the cause of early thrombosis, in the absence of other
factors, such as technical error, compressing haemato-
ma/seroma or proximal venous occlusion.
Perigraft seroma is a typical early complication of
PTFE AVGs.26 The most frequent late complication in
AVGs, particularly synthetic grafts, is stenosis at the
venous anastomosis due to development of myointi-
mal hyperplasia. Concomitant thrombosis requires
revisional surgery to preserve other access sites for
future use: surgical correction using an interposition
graft66,67 is generally preferred to endovascular repair,
because of its better long-term results.68 Multiple
stenoses within an AVG at needling sites do not
generally need of surgical correction.
As the graft is only a porous scaffold, a minimum of
three weeks is required before using an AVG to allow
capillary ingrowth, surface re-endothelialization and
host incorporation. The premature needling of an AVG
is associated with puncture site bleeding and false
aneurysm formation.
Tunneling too superficially, the use of anticoagulants
and infection are also potential causes of false
aneurysm development, skin erosion, infection and
hemorrhage. High systemic blood pressure, venous
hypertension due to a compromised venous outflow,
atherosclerosis69 and graft wall degeneration may leadto true aneurysms later on. Biological grafts, especially
those treated by glutaraldehyde, are reported to be
moreprone to biodegradation andaneurysmformation
or dilatation. Cannulation technique is also important
for prevent graft degeneration:70 the ‘rope ladder’
technique is, in our experience, much better for AVGs
than the ‘area puncture’ and ‘buttonhole’ techniques.
Vascular access-induced peripheral ischaemia, or
steal syndrome, is more frequent in forearm PTFE-
AVGs than radio-cephalic AVFs (4.3–6 vs 1–1.8%)71
and may be due to peripheral arteriosclerosis,
diabetes, too large anastomosis, anatomical anomalies
of the palmar arch, age, previous ipsilateral AVFs and
high flow. If left untreated, it may lead to digital
gangrene or even hand amputation.72 In addition, to
preoperative investigations (bilateral measurement of
arm and digital blood pressures, digital/brachial
pressure indices and, in selected cases, upper limb
angiography or magnetic resonance angiography), the
best way to prevent steal syndrome is by restricting the
arteriotomy to less than 80% of the arterial diameter.
Biologic grafts are preferable, although more expens-
ive than PTFE grafts, as they can more easily be
pleated to match the graft to a smaller arteriotomy.
Currently, the most frequent cause of AVG failure is
stenosis or thrombosis of the great veins, due to central
vein catheterization, which leads to increased recircu-
lation, decreased urea clearance, swelling and even
ulceration of the ipsilateral limb. Percutaneous
transluminal angioplasty, with or without stenting is
helpful, but restenosis usually occurs within few
months so that graft ligation may become necessary.Graft Infection
The risk of infection of AVGs is significantly greater
than AVFs.73 This is important because dialysis access-
related infection is associated with substantial mor-
bidity and mortality.74
Oral linezolid is a new treatment option in the
management of methicillin-resistant Staphylococcus
aureus (MRSA) infections, and seems to have signifi-
cantly better outcomes than intravenous vancomycin.75
Surgical treatment strategies vary according to the
time of onset of the infection, the patient’s clinical
condition, the access site, the nature of the graft
material and its anatomical position. Immediate
removal of the access graft should be performed in
cases of early (within 1 month) infections arising close
to arterial anastomosis or in deep infection in lower
limb AVGs. By contrast, a conservative approach may
be adopted in late AVG infections away from the
arterial anastomosis, such as superficial infections inEur J Vasc Endovasc Surg Vol 32, August 2006
Fig. 5. (A) An infected forearmAVG has been just treated by partial excision; a new organic interposition graft is anastomosed
in an end-to-end fashion to the arterial limb of the old AVG. (B) The new interposition graft bypasses the infected area
involved through a new, concentric, subcutaneous tunnel. (C) The skin incisions are closed and covered with occlusive
dressing. (D) The infected area is treated by removing the AVG and leaving the wound to heal by second intention.
L. Berardinelli208true graft aneurysms or in midgraft AVG infections, as
shown in Fig. 5. Primary removal of the entire graft
should be reserved for extensive infections of synthetic
AVGs.
In a prospective study of Minga,76 of more than 500
dialysis patients over a 4.5 year-period, 90 (18%)
functioning PTFE-AVGs were removed because of
infection. During the same period, there were 1.1 graft-
years of follow-up, yielding a rate of 8.2 infections/100
graft-years and 1% of related-deaths. In a recent
retrospective study,77 significantly better results
were obtained with 863 AVGs performed in the
upper (701) or in the lower (116) limb between JanuaryEur J Vasc Endovasc Surg Vol 32, August 20061990 and June 2005, using biologic/semibiologic
materials, in comparison with previous studies on
PTFE AVGs (2.6 infections/100 graft-years were
observed over 2.3 graft-years of follow-up), with a
significantly lower incidence of functioning graft loss
for infection (2.9%) and of related deaths (0.1%).Conclusion
Organic and semi-organic materials for AVG construc-
tion offer advantages over synthetic materials, with
easier to handling, a lower incidence of ‘steal
AV Grafts for Dialysis 209syndrome’, wider possibilities for the preservation of
the patient’s native vessels and a lower incidence of
infection. Thrombogenicity of the luminal surface is
the most common cause of AVG occlusion. Biological
prostheses give more satisfactory results for revision
vascular access surgery, prolong access patency and
improve the quality of life, even in difficult patients.Key Summary
† Biologic/semibiologic grafts give better long term
patencies, a lower incidences of infection and steal
syndrome, a very low incidence of stenosis at the
venous end and easier redo-surgery in comparison
with synthetic grafts.
† The creation of loop or straight AVGs should not
simply depend on the preference of the vascular
surgeon: every effort must be made to preserve the
native vessels of uremic patients, using the most
compliant graft and a critical strategy for sequential
AVG placement
† The improved compliance of biological/semibiolo-
gical grafts is advntageous when crossing joints
and allows some techniques which would other-
wise not be possible, helping to preserve the
vascular system for future access sites
† Avoid synthetic prostheses in the elderly, diabetics
and very young patients, as they are more prone to
infection and steal syndrome
† The arteriotomy should not exceed 80% of the
arterial diameter to avoid a steal syndrome: the
advantage of biologic or semibiologic materials is
that they may be easily ‘pleated’ to match the
length of the arteriotomy.
† Avoid puncturing biological AVGs for a minimum
of 3 weeks after implantation to prevent bleeding or
false-aneurysm formation
† An aggressive surgical approach limits the con-
sequences of AVG infection
† It is important to minimize central venous catheter
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